GNCA News and Press, Genocea Biosciences Inc. From 07/29/21

Genocea Biosciences, Inc. (GNCA) Q2 2021 Earnings Conference Call July 29, 2021 08:30 AM ET Company Participants Dan Ferry - Investor Relations, LifeSci Advisors Chip Clark - President & Chief Executive Officer Diantha Duvall - Chief Financial Officer Tom Davis - Chief Medical Officer Jes...

The following slide deck was published by Genocea Biosciences, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Genocea Biosciences, Inc. 2021 Q2 - Results - Earnings Call Presentation

GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues GEN-009 neoantigen vaccine candidate shows promising long-term clinical results Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Ge...

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its second quarter 2021 financial results and corporate update conference call and live audio webcast on...

Genocea Biosciences (GNCA) announces the dosing of the first patient in its TiTAN study, a Phase 1/2a clinical trial testing its GEN-011 therapy in certain patients with cancer.The company expects to report top-line results from the study on a subset of patients late in the fourth quarte...

CAMBRIDGE, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the dosing of the first patient in its TiTAN study, a Phase 1/2a clinical trial testing its GEN-01...

Four of nine checkpoint inhibitor-sensitive patients experienced RECIST responses post vaccination; median duration without disease progression after initial GEN-009 vaccination was 15 months Two of seven CPI-refractory patients experienced stable disease for up to 10 months after...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

I operate two main portfolios: my "safe" portfolio and my high growth portfolio. This article will dissect and focus on my high-growth holdings. I generally like to invest in themes and tend to take a shotgun approach to my holdings in emerging sectors. I will list my holdings for 8 s...

Genocea Biosciences, Inc. (GNCA) Q1 2021 Results Conference Call April 29, 2021 08:30 AM ET Company Participants Dan Ferry - Investor Relations Chip Clark - President and Chief Executive Officer Diantha Duvall - Chief Financial Officer Tom Davis - Chief Medical Officer Jessica Flechtner - Chi...